Real-World Effectiveness of Perinatal RSV Immunoprophylaxis

Status Not yet recruiting

Clinical Trial Summary

The purpose of this study is to continue evaluating how well the RSV vaccines work as they are currently being used in routine clinical practice. Some of the questions that the investigators hope to answer with this study are: 1) What is the overall effectiveness of these vaccines? 2) How long does immunity last? 3) How effective are the vaccines against new strains? 3) Does the vaccine's effectiveness vary by age?

Clinical Trial Description

This will be a large-scale case-control study aiming to evaluate the effectiveness of perinatal RSV immunoprophylaxis. Cases and controls will be identified using active surveillance in both inpatient and outpatient clinical sites of the Yale New Haven Health System. Investigators will enroll patients seeking health care for acute respiratory illness and confirm RSV infection using approved molecular assays. Data will be collected from multiple sources, including health records, interviews, immunization registries, and population-based surveys. Investigators will generate estimates of effectiveness for each type of immunization used, disaggregated by time from immunization, disease severity, and sociodemographic characteristics (Aim 1). Investigators will also perform genetic characterization of all RSV viruses in the study, monitor the genetic diversity of the virus over time, and quantify the relative effectiveness of immunoprophylaxis against various viral lineages (Aim 2). Finally, investigators will collect acute and convalescent blood from a subset of infants and employ a single-cell and multi-omics approach to study the dynamics of the innate and adaptive immune responses during RSV infection and explore the molecular mechanisms that contribute to immunoprophylaxis failure (Aim 3). ;

Study Design

Related Conditions & MeSH terms

Respiratory Syncytial Virus Infections
RSV Infection

Clinical Trial Details

NCT number	NCT06172660
Study type	Observational
Source	Yale University
Contact	Carlos R Oliveira, MD
Phone	203-785-5474
Email	carlos.oliveira@yale.edu
Status	Not yet recruiting
Phase
Start date	July 1, 2024
Completion date	December 30, 2028

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03698084` - RESCEU: Defining the Burden of RSV Disease
Recruiting	`NCT05550545` - Infant RSV Infections and Health-related Quality of Life of Families
Completed	`NCT05587478` - A Study of EDP-323 in Healthy Subjects	Phase 1
Recruiting	`NCT06180993` - Evaluation of the Effectiveness and Impact of Nirsevimab Administered as Routine Immunization
Suspended	`NCT03909867` - Emission Patterns of Respiratory Syncytial Virus
Recruiting	`NCT06259487` - Coordinated Vaccination Against RSV and Influenza in Patients With Chronic Heart Failure and Its Impact on Prognosis.	N/A
Not yet recruiting	`NCT04144816` - Predictors of Respiratory Syncytial Virus (RSV) Hospitalizations in Infants
Completed	`NCT01090557` - Exhaled Nitric Oxide in Respiratory Syncytial Virus (RSV) Bronchiolitis: a Pilot Study	N/A
Terminated	`NCT01475305` - Intranasal Challenge of Healthy Adults With Respiratory Syncytial Virus (RSV)	Phase 1
Not yet recruiting	`NCT05928507` - FINDER® Instrument and FINDER® FLU A/B, RSV, SARS-CoV-2 Test Clinical Evaluation Protocol
Completed	`NCT03062917` - Nasal and Bronchial Absorption Sampling in RSV Bronchiolitis	N/A
Completed	`NCT03691623` - A Phase 2a Study to Evaluate EDP-938 in the Virus Challenge Model	Phase 2
Completed	`NCT03387137` - Evaluating the Infectivity, Safety, and Immunogenicity of a Respiratory Syncytial Virus Vaccine (RSV 6120/∆NS2/1030s) in RSV-Seropositive Children and RSV-Seronegative Infants and Children	Phase 1
Completed	`NCT05070975` - Severity of RSV Infections in Twins
Recruiting	`NCT04938830` - Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007)	Phase 3
Recruiting	`NCT05568706` - A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.	Phase 2
Completed	`NCT03755778` - Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinidine in Healthy Subjects	Phase 1
Completed	`NCT01483911` - ALX-0171 Phase I Study, Evaluating Single Ascending Dose and Multiple Dose in Healthy Male Volunteers	Phase 1
Recruiting	`NCT06170242` - A Controlled Phase 2a Study to Evaluate the Efficacy of EDP-323 Against Respiratory Syncytial Virus Infection in a Virus Challenge Model	Phase 2
Completed	`NCT03750383` - Drug-Drug Interaction Study Between EDP-938, Cyclosporine and Prednisone in Healthy Adult Subjects	Phase 1